Home›Companies›Biotech & Pharma›ICB

Immuno Cancer Biotherapeutics, Inc.

Develops antibody-based therapies intended to treat cancer.

No LinkedIn page we could confirm. Why?
Updated Nov 9, 2026·Latest SEC filing Oct 15, 2026·Suggest an edit

About ICB

ICB is a private company based in Canton, South Dakota, incorporated in 2024 in Delaware. It has reported $75,000 raised in one offering on Form D since October 2026.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Oct 9, 2026Oct 15, 2026$75,000target not set3$25,000SAFE (Simple Agreement for Future Equity)Rule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on ICB's Form D filed Oct 15, 2026.

JR
James Robl
Co-founder, President and CSO, director
SC

Sources

  1. SECImmuno Cancer Biotherapeutics, Inc. filing history